- Home
- TVTX
as 10-24-2025 3:52pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Upcoming Earnings Alert:
Get ready for potential market movements as Travere Therapeutics Inc. TVTX prepares to release earnings report on 30 Oct 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.5B | IPO Year: | N/A |
| Target Price: | $34.86 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.91 - $28.85 | Next Earning Date: | 10-30-2025 |
| Revenue: | $333,865,000 | Revenue Growth: | 87.94% |
| Revenue Growth (this year): | 83.23% | Revenue Growth (next year): | 41.49% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Sep 22 '25 | Sell | $25.00 | 10,000 | $250,000.00 | 89,878 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 4 '25 | Sell | $19.71 | 119 | $2,345.49 | 92,083 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 3 '25 | Sell | $18.20 | 454 | $8,262.80 | 92,083 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Aug 27 '25 | Sell | $17.31 | 470 | $8,135.70 | 92,083 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Investor's Business Daily
a month ago
Hims & Hers Leads 15 Growth Stocks Amid Medical Boom
Business Wire
a month ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Insider Monkey
a month ago
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Zacks
a month ago
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Investor's Business Daily
a month ago
Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High
Simply Wall St.
a month ago
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.